In Japan, the Designated Marketing Authorization Holder (DMAH) is not directly responsible for pricing and reimbursement submissions. These tasks are typically handled by the Marketing Authorization Holder (MAH) or the pharmaceutical company itself, which collaborates with relevant authorities to navigate the complex pricing and reimbursement landscape in Japan.